COMMUNIQUÉ DE PRESSE publié le 24/01/2024 à 14:00, il y a 2 années 3 mois AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement AiCuris and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to discover new active agents for the treatment and prophylaxis of infections of immunocompromised patients. The partnership aims to develop novel therapies for patients with high medical need. The financial details of the collaboration were not disclosed. For more information, visit www.dzif.de and www.aicuris.com. AiCuris German Center For Infection Research Collaboration License Option Agreement Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 28/09/2023 à 14:00, il y a 2 années 7 mois AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 23/08/2023 à 14:00, il y a 2 années 8 mois AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS® (letermovir) in Second Indication
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 14:00, il y a 2 années 10 mois AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients
COMMUNIQUÉ DE PRESSE publié le 04/04/2023 à 14:00, il y a 3 années 1 mois AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary
Publié le 07/05/2026 à 19:15, il y a 1 jour 20 heures 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 1 jour 20 heures Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 1 jour 20 heures Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 1 jour 20 heures Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 1 jour 20 heures ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 09/05/2026 à 01:30, il y a 13 heures 55 minutes Star Copper Announces Agreement with Zimtu Capital Corp.
Publié le 09/05/2026 à 00:00, il y a 15 heures 25 minutes Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Publié le 08/05/2026 à 20:38, il y a 18 heures 47 minutes EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Publié le 08/05/2026 à 19:12, il y a 20 heures 12 minutes EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Publié le 08/05/2026 à 19:02, il y a 20 heures 23 minutes Metall Zug – Annual General Meeting of Shareholders approves all proposals
